Enasidenib: a new drug for the treatment of acute myeloid leukaemia
YAN Li-li
MA Shuai
HUANG Li
Abstract：Enasidenib is a first-in-class isocitrate dehydrogenase-2 inhibitor approved by FDA on August1, 2017. It was developed by Celgene Corporation and indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Its pharmacodynamics, pharmacokinetics, clinical study and adverse reaction were reviewed in this paper.
Keywords：enasidenibisocitrate dehydrogenase-2 inhibitoracute myeloid leukaemiaclinical study
Publication Date：2018-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 1718-1720 )